Title: A clinic study of lamivudine on the treatment of children with chronic hepatitis B
Abstract: Objective To observe the clinic effect of lamivudine in children with chronic hepatitis B and its influence of HBV markers.Methods 63 children with chronic hepatitis B were divided into two groups randomly.All the 28 cases in the control group were treated with silybin meglumine tablet and glycyrrhizic acid tablet and the 35 cases in the treatment group,with lamivudine 3mg/kg or so in addition to the treatment given in the control group.The two groups were treated for 2 years and one year following-up was performed observing changes in WBC,BPC,Cr,liver function and peripheral blood HBV markers.Results There was no significant deviation of WBC,BPC and Cr between the two groups(P0.05).By the end of the treatment course ALT recovery rate was 94.3% for the treatment group and 53.6% for the control group(P0.01);HBV DNA negative rate was 88.6% for the treatment group and 3.6% for the control group(P0.01);HBeAg negative rate was 54.3% for the treatment group and 3.6% for the control group(P0.01);anti-HBe positive rate was 48.6% for the treatment group and 3.6% for the control group(P0.01).One year later,the ALT recovery rate was 74.3% for the treatment group and 42.9% for the control group(P0.05);HBV DNA negative rate was 45.7% for the treatment group and 3.6% for the control group(P0.01);HBeAg/anti-HBe transision rate was 45.7% for the treatment group and 3.6% for the control group(P0.01).Conclusion Lamivudine is a safe and effective medicine in treating children with chronic hepatitis B.
Publication Year: 2004
Publication Date: 2004-01-01
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot